anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Amiodarone
Trial phase: Phase 3
ATC code: C01BD01
SMILES: CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 972
Group description: Intravenous (IV) or intraosseous (IO) administration of amiodarone if VF/pulseless VT reoccurs after initial defibrillation.

amiodarone: 300 mg will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 150 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 150 mg, followed by a second dose of 150 mg if the VF/pulseless VT persists.
Eligibility criteria:
Inclusion Criteria:

Age at least 18 years or local age of consent
Non-traumatic out-of-hospital cardiac arrest treated by Resuscitation Outcomes Consortium (ROC) emergency medical services (EMS) with advanced life support capability
VF or pulseless VT presenting as the initial arrest arrhythmia or results from conversion of another arrhythmia (such as transient asystole or pulseless electrical activity)
Incessant or recurrent VF/VT after receipt of ≥ 1 shocks
Established vascular access

Exclusion Criteria:

Asystole or pulseless electrical activity (PEA) as the initial arrest rhythm who never transition to VF or pulseless VT
Written advance directive to not attempt resuscitation (DNAR)
Blunt, penetrating, or burn-related injury
Exsanguination
Protected populations (prisoners, pregnancy, children under local age of consent)
Treated exclusively by non-ROC EMS agency/provider, or by basic life support-only capable ROC EMS providers
Prior receipt of open label lidocaine or amiodarone during resuscitation
Intervention: Acetaminophen
Trial phase: Phase 3
ATC code: N02AJ01 | N02AJ06 | N02AJ13 | N02AJ17 | N02BE01 | N02BE51 | N02BE71
SMILES: CC(=O)Nc1ccc(O)cc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 87
Group description: Hydrocodone 5mg / Acetaminophen 500mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.

Hydrocodone (first trial): Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain
Eligibility criteria:
Inclusion Criteria:

patient has complaint of acute extremity pain (less than 7 days duration)
clinician plans to discharge on oral pain medication

Exclusion Criteria:

patients on methadone
chronic pain condition such as sickle cell anemia or fibromyalgia
history of adverse reaction to one of the study medications
taken prescribed opioids in the past 24 hrs
have a medical condition that might alter the metabolism of one of the study medications (i.e. hepatitis, renal insufficiency, thyroid disease, Adrenal disease)
Take a medication that might interact with one of the study medications
Intervention: Oxycodone
Trial phase: Phase 3
ATC code: N02AA05 | N02AA55 | N02AA56 | N02AJ17 | N02AJ18 | N02AJ19
SMILES: COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 111
Group description: Oxycodone 5mg / Acetaminophen 325mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.

Oxycodone (for second trial): Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain
Eligibility criteria:
Inclusion Criteria:

patient has complaint of acute extremity pain (less than 7 days duration)
clinician plans to discharge on oral pain medication

Exclusion Criteria:

patients on methadone
chronic pain condition such as sickle cell anemia or fibromyalgia
history of adverse reaction to one of the study medications
taken prescribed opioids in the past 24 hrs
have a medical condition that might alter the metabolism of one of the study medications (i.e. hepatitis, renal insufficiency, thyroid disease, Adrenal disease)
Take a medication that might interact with one of the study medications
Intervention: Oxycodone
Trial phase: Phase 3
ATC code: N02AA05 | N02AA55 | N02AA56 | N02AJ17 | N02AJ18 | N02AJ19
SMILES: COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 105
Group description: Oxycodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.

Oxycodone (third trial): Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain
Eligibility criteria:
Inclusion Criteria:

patient has complaint of acute extremity pain (less than 7 days duration)
clinician plans to discharge on oral pain medication

Exclusion Criteria:

patients on methadone
chronic pain condition such as sickle cell anemia or fibromyalgia
history of adverse reaction to one of the study medications
taken prescribed opioids in the past 24 hrs
have a medical condition that might alter the metabolism of one of the study medications (i.e. hepatitis, renal insufficiency, thyroid disease, Adrenal disease)
Take a medication that might interact with one of the study medications
Intervention: Methotrexate
Trial phase: Phase 4
ATC code: L01BA01 | L04AX03
SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 47
Group description: Patients started on 7.5 mg of oral methotrexate (weekly) increased by 2.5 mg every 2 weeks (max 25mg weekly)
Eligibility criteria:
Inclusion Criteria:

Patients with rheumatoid arthritis fulfilling the ACR 1987 criteria
Between 18 years to 65 year of age
Having active disease Disease activity score (28 joints) DAS28-3 more than 5.1
Not on methotrexate in the last 2 months
Permitted to be on corticosteroids if the dosages stable for at least 1 weeks before randomization and if corticosteroid dosage less than 10 mg/day
Permitted to be on other disease modifying anti-rheumatic drug (DMARD) like sulfasalazine, leflunomide and hydroxychloroquine, if dosages stable for at least 2 weeks before randomization

Exclusion Criteria:

Pregnant/Breastfeeding
Ongoing/Recent treatment with methotrexate (2 months)
Chronic liver disease
Renal failure
Any leucopenia or thrombocytopenia
Breast-feeding
Desirous of pregnancy in the next 6 months
Known Hepatitis B or C positive
Known clinically relevant chronic lung disease: ILD
Tuberculosis or other active infections
Known HIV positive
Intervention: Methotrexate
Trial phase: Phase 4
ATC code: L01BA01 | L04AX03
SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 53
Group description: Patients started on 15 mg of oral methotrexate (weekly) increased by 2.5 mg every 2 weeks (max 25mg weekly)
Eligibility criteria:
Inclusion Criteria:

Patients with rheumatoid arthritis fulfilling the ACR 1987 criteria
Between 18 years to 65 year of age
Having active disease Disease activity score (28 joints) DAS28-3 more than 5.1
Not on methotrexate in the last 2 months
Permitted to be on corticosteroids if the dosages stable for at least 1 weeks before randomization and if corticosteroid dosage less than 10 mg/day
Permitted to be on other disease modifying anti-rheumatic drug (DMARD) like sulfasalazine, leflunomide and hydroxychloroquine, if dosages stable for at least 2 weeks before randomization

Exclusion Criteria:

Pregnant/Breastfeeding
Ongoing/Recent treatment with methotrexate (2 months)
Chronic liver disease
Renal failure
Any leucopenia or thrombocytopenia
Breast-feeding
Desirous of pregnancy in the next 6 months
Known Hepatitis B or C positive
Known clinically relevant chronic lung disease: ILD
Tuberculosis or other active infections
Known HIV positive
Intervention: Spironolactone
Trial phase: Not Applicable
ATC code: C03DA01
SMILES: [H][C@]12CC[C@]3(C)[C@]4(CCC(=O)O4)CC[C@@]3([H])[C@]1([H])[C@]([H])(SC(C)=O)CC1=CC(=O)CC[C@@]12C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: Spironolactone 50 mg once daily for 6 weeks.
Eligibility criteria:
Inclusion Criteria:

Age 18-70 years
Good health as evidenced by history and physical exam
Body Mass Index (BMI): >30 kg/m2 and <45 kg/m2

Exclusion criteria:

Medical illnesses other than treated hypothyroidism
Blood Pressure (BP) >135/85 or systolic BP <90 mm Hg
Hepatic disease (transaminase > 3 times normal)
Renal impairment (Creatinine clearance <60 ml/min)
Baseline serum Potassium (K) >5.0 mmol/L
History of drug or alcohol abuse
Allergies to spironolactone
Participation in any other concurrent clinical trial
Women using oral contraceptives within the last 3 months
Intervention: Topiramate
Trial phase: Not Applicable
ATC code: A08AA51 | N03AX11
SMILES: [H][C@@]12OC(C)(C)O[C@]1([H])CO[C@@]1(COS(N)(=O)=O)OC(C)(C)O[C@]12[H]
Sex: Male
Age groups: Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Topiramate arm will be titrated (dose will increase slowly) over 6 weeks to 400mg or highest tolerated dose.

Topiramate: Topiramate titrated over 6 weeks to 400mg or highest tolerated dose.
Eligibility criteria:
Inclusion Criteria:

Male
Ages 21-64
Diagnosis of PTSD via a score of 50 or higher on the Clinician Administered PTSD Scale (CAPS)
Alcohol abuse or dependence per diagnosis in the medical record -or- by consuming more than 35 standard drinks per week over the previous 4 weeks as measured by the Timeline Follow-Back Interview
A desire to reduce drinking behavior
Any Race/Ethnicity

Exclusion Criteria:

Currently taking a carbonic anhydrase inhibitor (e.g. zonisamide, acetazolamide, dichlorphenamide)
Currently taking or have taken in the previous 3 months: acamprosate, naltrexone, disulfiram, topiramate
Change in benzodiazepine dose within the previous 3 months
Change in other (non-benzodiazepine) medication dose within the last 4 weeks
Seizure disorder documented in the medical record
Head trauma with loss of consciousness for greater than 30 minutes -or- a diagnosis of post-concussive syndrome documented in the medical record
Suicide attempt within the previous 3 months or suicidal ideation within the previous 4 weeks
A history of kidney stones
A history of glaucoma
ALT or AST liver enzymes elevated more than twice the upper limit of normal
More than 4 unsuccessful attempts at inpatient alcohol treatment
Medically unstable (including significant hypertension despite adequate treatment)
A history of delirium tremens ("DTs") or alcohol withdrawal seizure
Compulsory treatment to avoid legal consequences (e.g. imprisonment)
Currently in a setting without access to alcohol (e.g. locked inpatient unit)
Intervention: Acetaminophen
Trial phase: Phase 3
ATC code: N02AJ01 | N02AJ06 | N02AJ13 | N02AJ17 | N02BE01 | N02BE51 | N02BE71
SMILES: CC(=O)Nc1ccc(O)cc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 111
Group description: Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally

Acetaminophen: Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours
Eligibility criteria:
Inclusion Criteria:

Provides written informed consent before initiation of any study-related procedures.
Males and females aged at least 10 years and not more than 60 years old on the day of consent.
Undergoing dental surgery for the extraction of at least 2 impacted third molar teeth.
A resting VAS pain intensity score at baseline (within 6 hours after the completion of surgery) of greater than or equal to 40 mm on a 100 mm VAS scale with 0 = no pain and 100 = worst pain imaginable.

Exclusion Criteria:

Has taken any NSAID or acetaminophen within 12 hours prior to the stat of surgery other than asprin less than or equal to 150 mg/day
Subjects who have received any anaesthetics within 24 hours prior to surgery
Hypersensitivity to opioids
Known to be pregnant or possibly pregnant
Women of childbearing potential who are unwilling to take adequate contraceptive precautions, i.e., hormonal contraceptive, an intrauterine device, double-barrier method, or abstinence. A women of childbearing potential is defined as any female who is less than 2 years post-menopausal or has not undergone a partial or total hysterectomy or surgical sterilization, e.g. bilateral tubal ligation, bilateral oophorectomy.
Women of childbearing potential who are unwilling to undergo an urine pregnancy test.
Suffering from a neurological disorder relating to pain perception or any acute or chronic condition that, in the opinion of the investigator, makes the subject unsuitable from an efficacy or safety perspective.
In the opinion of the investigator, unable to understand the visual analogue pain score or comply with the protocol requirements.
Currently, or in the last 30 days, has been in a clinical trial involving another study drug.
Currently treated with an ACE inhibitor, warfarin, steroid (other than nasal steroids or topical steroids with the approval of the investigator) cyclosporin, tacrolimus or methotrexate, or any other medication felt by the investigator to interfere with safety or efficacy evaluations.
Participant weight < 50 kg or > 120 kg.
Has a history of drug or alcohol abuse.
Suffering from any other disease or condition which, in the opinion of the investigator, means that it would not be in the participants best interests to participant in the study.
Intervention: Quercetin
Trial phase: Phase 4
SMILES: O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1051
Group description: Polyethylene glycol: HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L
Eligibility criteria:
Inclusion Criteria:

Between 18 and 70 years of age, inclusive
Scheduled for colonoscopy within 21 days of the screening visit
Able to swallow tablets the size of a multivitamin without difficulty

Exclusion Criteria:

History of biopsy-proven acute phosphate nephropathy
Known allergy or hypersensitivity to treatment arms
History of gastric stapling or bypass procedure or history of gastric retention
History of any other sodium phosphate preparation within 6 months prior to colonoscopy
Intervention: Gadofosveset
Trial phase: Not Applicable
ATC code: V08CA11
SMILES: O.O=C([O-])CN(CCN(CC(=O)[O-])CC(COP(=O)([O-])OC1CCC(c2ccccc2)(c2ccccc2)CC1)N(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3].[Na+].[Na+].[Na+]
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: gadofosveset : Intravenous administration of the specified dosage of gadolinium contrast agent
Eligibility criteria:
Inclusion Criteria:

healthy male or female subjects between 18-45 years of age

Exclusion Criteria:

Pregnant and lactating females
known renal impairment
allergy to gadolinium-based contrast
metallic implanted devices
claustrophobia.
Intervention: Gadofosveset
Trial phase: Not Applicable
ATC code: V08CA11
SMILES: O.O=C([O-])CN(CCN(CC(=O)[O-])CC(COP(=O)([O-])OC1CCC(c2ccccc2)(c2ccccc2)CC1)N(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3].[Na+].[Na+].[Na+]
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: FDA-approved dose for lower extremity arterial imaging

gadofosveset : Intravenous administration of the specified dosage of gadolinium contrast agent
Eligibility criteria:
Inclusion Criteria:

healthy male or female subjects between 18-45 years of age

Exclusion Criteria:

Pregnant and lactating females
known renal impairment
allergy to gadolinium-based contrast
metallic implanted devices
claustrophobia.
Intervention: Cholic Acid
Trial phase: Phase 3
ATC code: A05AA03
SMILES: [H][C@@]1(O)CC[C@@]2(C)[C@@]([H])(C1)C[C@@]([H])(O)[C@@]1([H])[C@]3([H])CC[C@]([H])([C@]([H])(C)CCC(=O)O)[C@@]3(C)[C@@]([H])(O)C[C@]21[H]
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 53
Group description: Active drug

Cholic Acid: 10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
Eligibility criteria:
Inclusion Criteria:

Subjects who received cholic acid through CCHMC protocols 91-10-10 or CAC-002-01 and meet the following criteria are eligible for study participation.

The subject and/or parent/legal guardian must have provided informed consent prior to study start.
The subject must have a diagnosis of an inborn error of bile acid synthesis.
The subject must be willing and able to comply with all study assessments and procedures.
Subjects with other organ dysfunction will not be excluded
Intervention: Lycopene
Trial phase: Phase 2
SMILES: CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 26
Group description: Lycopene 30 mg/day until clinically-indicated repeat biopsy performed (approximately 6 months)
Eligibility criteria:
Inclusion Criteria:

Male
Have a history of prostate biopsy indicating HGPIN without cancer within 2 years prior to registration. At least 4 weeks must have elapsed between the last biopsy and the biopsy used for baseline data.
Have an AUA symptom score <=25 at time of registration.
Refrain from taking lycopene, selenium, vitamin E, or other antioxidant supplements within 1 month of randomization. Participants must agree to refrain from taking non-study dietary supplements while on study
Refrain from taking exogenous hormones, drugs affecting hormone metabolism, or specified non-prescription substances (e.g. saw palmetto, PC-Spes) taken to affect the prostate within 1 month of registration. Patients must also agree to refrain from taking the non-prescription substances while on study
Be willing to limit intake of lycopene-containing foods while on study
Have no prior cancer (except basal cell or squamous cell skin cancer) or complete remission for at least 5 years
Be ambulatory, capable of self-care and able to carry out light or sedentary work
Have a dietary fat intake of 23-48% of calories
Participant's physician recommends repeat biopsy 4-6 months after randomization

Exclusion Criteria:

No repeat biopsy planned
Not willing to change diet
Have a diagnosis of prostate cancer
Intervention: Tadalafil
Trial phase: Phase 3
ATC code: C02KX52 | C02KX54 | G04BE08 | G04CA54 | G04CB51
SMILES: [H][C@]12Cc3c([nH]c4ccccc34)[C@@H](c3ccc4c(c3)OCO4)N1C(=O)CN(C)C2=O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 36
Group description: 20 mg Tadalafil tablet taken by mouth once a day for 3 months

Tadalafil: 20 mg Tadalafil taken once a day for 3 months
Eligibility criteria:
Inclusion Criteria:

Age > 18 years and < 50 years
BMI > 30 kg/m2
Fasting insulin > 10 uU/mL

Exclusion Criteria:

Systolic blood pressure (SBP) < 100, > 150 mmHg
Current anti-hypertensive medication use, including diuretics
Current use of organic nitrates
Current use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil)
History of reaction to PDE-5 inhibitors
Known HIV infection
Use of medications that strongly alter CYP3A4 activity
History of myocardial infarction, angina, uncontrolled cardiac arrhythmia, stroke, transient ischemic attack, or seizure
Known non-arteritic ischemic optic retinopathy (NAIOR)
History of hearing loss
Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2 by the modified diet in renal disease (MDRD) equation
Hepatic transaminase (AST and ALT) levels greater than three times the upper limit of normal
Known pregnancy or those unwilling to avoid pregnancy during the course of the study
History of priapism
Use in excess of four alcoholic drinks daily
History of diabetes mellitus or use of anti-diabetic medications
Known anemia (men, Hct < 38% and women, Hct < 36%)
Intervention: Tretinoin
Trial phase: Phase 4
ATC code: D10AD01 | D10AD04 | D10AD51 | D10AD54 | D10BA01 | D11AH04 | L01XF01 | L01XF02
SMILES: CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 109
Group description: Isotretinoin: Isotretinoin 20mg daily for 12 weeks
Eligibility criteria:
Inclusion Criteria:

18-70 year-old men or 50-70 year-old, post-menopausal women.
Healthy enough to participate in the study.
Willing and able to consent to participation.
Recurrent PVR-associated RD occurring at least 2 weeks after RD repair or
Primary RD (retinal detachment) associated with one or more high-risk features

Exclusion Criteria:

History of hypersensitivity to isotretinoin.
Current use of a corticosteroid (excluding topical).
Any history of depression, anorexia, liver or pancreatic disease.
More than one prior surgical RD repair.
Patients with closed funnel retinal detachments.
Patients with chronic retinal detachment, defined as longer than 12 weeks.
Any use an oral retinoid within 6 months.
Systemic chemotherapy within 6 months.
Patients taking supplemental vitamin A.
Corneal opacity sufficient to impair surgical view.
Proliferative diabetic retinopathy.
Intervention: Tretinoin
Trial phase: Phase 4
ATC code: D10AD01 | D10AD04 | D10AD51 | D10AD54 | D10BA01 | D11AH04 | L01XF01 | L01XF02
SMILES: CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 109
Group description: Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy

Isotretinoin: Isotretinoin 20mg daily for 12 weeks
Eligibility criteria:
Inclusion Criteria:

18-70 year-old men or 50-70 year-old, post-menopausal women.
Healthy enough to participate in the study.
Willing and able to consent to participation.
Recurrent PVR-associated RD occurring at least 2 weeks after RD repair or
Primary RD (retinal detachment) associated with one or more high-risk features

Exclusion Criteria:

History of hypersensitivity to isotretinoin.
Current use of a corticosteroid (excluding topical).
Any history of depression, anorexia, liver or pancreatic disease.
More than one prior surgical RD repair.
Patients with closed funnel retinal detachments.
Patients with chronic retinal detachment, defined as longer than 12 weeks.
Any use an oral retinoid within 6 months.
Systemic chemotherapy within 6 months.
Patients taking supplemental vitamin A.
Corneal opacity sufficient to impair surgical view.
Proliferative diabetic retinopathy.
Intervention: Sirolimus
Trial phase: Not Applicable
ATC code: L01EG04 | L04AA10 | S01XA23
SMILES: COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 54
Group description: 15mg Rapamycin
Eligibility criteria:
Inclusion Criteria:

Male Veterans
Diagnosis of Posttraumatic Stress Disorder related to combat

Exclusion Criteria:

Hypersensitivity to Rapamycin
Organic brain damage (including unresolved Traumatic Brain Injury sequela)
Substance dependence in the last three months
On any immunosuppressant therapy
Prominent suicidal or homicidal features
Medical conditions: systemic infections, congestive heart failure, renal failure, hepatic failure
Intervention: Rocuronium
Trial phase: Not Applicable
ATC code: M03AC09
SMILES: [H][C@@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@@H](OC(C)=O)[C@@H]([N+]5(CC=C)CCCC5)C[C@@]34[H])[C@@]1(C)C[C@H](N1CCOCC1)[C@@H](O)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: Rocuronium dose 0.2 mg/kg
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesia (ASA) physical status class I or II.
Body mass index between 18 and 35 kg m-2.
No use of psychotropic or neuropsychiatric medications.
A airway assessment with no indication of a difficult intubation including a class I or II Mallampati airway and a mandible-to-hyoid distance of greater than three fingerbreadths.
Age between 18-75 years.

Exclusion Criteria:

Does not meet inclusion criteria.